| Chronic Obstructive Airway Disease
Ohtuvayre vs Tudorza Pressair
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Ohtuvayre vs Tudorza Pressair with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTudorza Pressair has a higher rate of injection site reactions vs Ohtuvayre based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tudorza Pressair but not Ohtuvayre, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ohtuvayre
Tudorza Pressair
At A Glance
Oral inhalation
Twice daily
PDE3/PDE4 inhibitor
Oral inhalation
Twice daily
Anticholinergic
Indications
- Chronic Obstructive Airway Disease
- Chronic Obstructive Airway Disease
Dosing
Chronic Obstructive Airway Disease 3 mg (one unit-dose ampule) twice daily, once in the morning and once in the evening, via oral inhalation using a standard jet nebulizer with a mouthpiece.
Chronic Obstructive Airway Disease One oral inhalation of 400 mcg twice daily (morning and evening approximately 12 hours apart).
Contraindications
- Hypersensitivity to ensifentrine or any component of this product
- Severe hypersensitivity to milk proteins
- Hypersensitivity to aclidinium bromide or any excipient
Adverse Reactions
Most common (>=1%) Back pain, hypertension, urinary tract infection, diarrhea
Serious Paradoxical bronchospasm, psychiatric events including suicidality
Most common (>=1%) Headache, nasopharyngitis, cough, diarrhea, sinusitis, rhinitis, toothache, fall, vomiting
Serious Paradoxical bronchospasm, worsening of narrow-angle glaucoma, worsening of urinary retention, immediate hypersensitivity reactions
Postmarketing Anaphylaxis, angioedema, urticaria, rash, bronchospasm, itching, nausea, dysphonia, blurred vision, urinary retention, tachycardia, stomatitis
Pharmacology
Ensifentrine is a dual inhibitor of PDE3 and PDE4 enzymes; inhibition results in accumulation of intracellular cAMP and/or cGMP, producing downstream bronchodilatory and anti-inflammatory signaling effects.
Aclidinium bromide is a long-acting antimuscarinic (anticholinergic) agent that inhibits M3 muscarinic receptors on airway smooth muscle, causing bronchodilation; the bronchodilatory effect is predominantly site-specific following inhalation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ohtuvayre
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
Tudorza Pressair
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Ohtuvayre
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (1/8)
Tudorza Pressair
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (0/8)
Humana
Ohtuvayre
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Tudorza Pressair
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Chronic Obstructive Pulmonary Disease (COPD)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Tudorza Pressair.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OhtuvayreView full Ohtuvayre profile
Tudorza PressairView full Tudorza Pressair profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.